OPKO Health, Inc. (LON:0KCS)
London · Delayed Price · Currency is GBP · Price in USD 1.409
-0.020 (-1.41%)
At close: Sep 12, 2025
OPKO Health Employees
OPKO Health had 2,997 employees as of December 31, 2024. The number of employees decreased by 933 or -23.74% compared to the previous year.
Employees
2,997
Change (1Y)
-933
Growth (1Y)
-23.74%
Revenue / Employee
161.72K GBP
Profits / Employee
-43.14K GBP
Market Cap
805.48M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,997 | -933 | -23.74% |
| Dec 31, 2023 | 3,930 | -266 | -6.34% |
| Dec 31, 2022 | 4,196 | -1,571 | -27.24% |
| Dec 31, 2021 | 5,767 | 498 | 9.45% |
| Dec 31, 2020 | 5,269 | -827 | -13.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
OPKO Health News
- 6 weeks ago - Opko Health (OPK) Q2 Revenue Falls 14% - The Motley Fool
- 6 weeks ago - OPKO Health (OPK) Advances Strategic Initiatives with Key Asset Sale - GuruFocus
- 6 weeks ago - OPKO Health outlines $640M–$660M 2025 revenue target as BioReference sale and pipeline advances drive profitability push - Seeking Alpha
- 6 weeks ago - OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 2 months ago - NextPlat Issues Interim CEO Update Shareholder Letter - PRNewsWire
- 2 months ago - OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium - GlobeNewsWire
- 3 months ago - OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy - Seeking Alpha